Entity > Corporation > US > New York City New York > Aclaris Therapeutics

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a pharmaceutical company that deals in identifying, developing, and commercialization of drugs and therapies to meet needs in dermatology, medical, and immunology sectors. Aclaris Therapeutics serves patients in the United States.

KINect® is Aclaris Therapeutics’ Proprietary Drug Discovery Platform: Aclaris Therapeutics, Inc. has a multi-stage portfolio of drug candidates based on KINect®. The Company's drug candidates are Zunsemetinib (ATI -450), ATI -1777 and ATI -2138. ATI -450 is an orally administered, selective small molecule MK2 inhibitor for the treatment of rheumatoid arthritis. ATI -1777, a topical JAK 1/3 inhibitor for the treatment of atopic dermatitis. It is also developing ATI -2138 as a potential treatment for T cell-mediated autoimmune diseases. The company is also developing oral inhibitors of intestinal flora JAK as a potential treatment for inflammatory bowel disease.

Aclaris Operates in Two Segments: Aclaris Therapeutics, Inc. operates in two segments: Therapeutics and Contract Research. The Therapeutics segment is engaged in identifying and developing innovative therapies to address significant unmet needs in immune-inflammatory diseases. The Contract Research segment is active in the provision of laboratory services.

Aclaris Therapeutics, Inc. Was Founded in 2012: The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Aclaris Therapeutics